Clinical Trial Update: Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study) [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/2 trial evaluating ramucirumab, trastuzumab, and paclitaxel in HER2-positive recurrent/metastatic gastric cancer is underway, with unknown st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Yonsei University | Conditions: Recurrent/Metastatic Gastric Cancer | Phase 1, Phase 2 | Status: UNKNOWN